Tuesday, March 28, 2023 7:53:23 AM
https://www.wsj.com/articles/a-spark-of-life-after-death-points-to-new-hope-for-blindness-11662303872
Recent KOD News
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform • PR Newswire (US) • 05/02/2024 08:30:00 PM
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 • PR Newswire (US) • 03/26/2024 10:15:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:23:00 PM
- Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting • PR Newswire (US) • 01/30/2024 11:30:00 AM
- Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/04/2024 09:15:00 PM
- Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/21/2023 09:15:00 PM
- Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 11/14/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 11:05:54 AM
- Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission • PR Newswire (US) • 11/06/2023 10:00:00 AM
- KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING • PR Newswire (US) • 11/02/2023 03:21:00 AM
- Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society • PR Newswire (US) • 10/11/2023 10:00:00 AM
- Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference • PR Newswire (US) • 09/08/2023 10:00:00 AM
- New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion • PR Newswire (US) • 09/07/2023 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 09:26:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:33:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:57 PM
- Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/14/2023 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 10:45:38 AM
- Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program • PR Newswire (US) • 07/24/2023 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2023 08:24:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2023 08:22:39 PM
- Kodiak Sciences to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2023 08:15:00 PM
- Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 05/15/2023 08:01:00 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM